PUS7

Across TCGA pan-cancer cohorts, PUS7 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PUS7 data layer compared with 24 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PUS7 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PUS7 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

LUAD, HNSC, and LSCC are the cancer types where PUS7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	II,III,IV	0.996	0.717	.005	38	view →
HNSC	DFS	Median	III,IV	0.665	0.905	.001	37	view →
LSCC	DFS	Median	II,III,IV	0.891	0.496	<.001	17	view →
PDAC	OS	Median	All	0.280	0.453	.005	9	view →
GBM	OS	Median	All	0.529	0.273	.019	4	view →
UCEC	DFS	Median	II,III,IV	0.882	0.518	.030	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PUS7–LUAD (DFS)

Open the LUAD breakdown →